Compare iShares Core S&P 500 ETF (IVV) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core S&P 500 ETF vs GeneDx Holdings Corp — how do they compare? iShares Core S&P 500 ETF trades at $781.97 (market cap $897.20B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: iShares Core S&P 500 ETF is far larger — about 444.2× GeneDx Holdings Corp's market cap, and iShares Core S&P 500 ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core S&P 500 ETF for 46 Days and GeneDx Holdings Corp for 19 Days on average.
| IVV | WGS | |
|---|---|---|
Market Cap | $897.20B | $2.02B |
Volume | 4,580,672 | 734,640 |
Sector | Broad Market / Factor | Health |
52-Week High | $782.58 | $167.51 |
52-Week Low | $634.93 | $34.51 |
Typical Hold Time | 46 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $777.38, down 0.41% on the day, with a bullish technical signal from moving averages and neutral oscillators. Support lies at $775 and resistance at $780. Recent news highlights strong 2026 earnings growth expectations of 35% but a projected slowdown to 15% in 2027, with valuation debates ongoing amid index concentration risks.
The outlook remains cautiously optimistic given bullish technicals and Wall Street's long-term growth projections, but risks include profit growth deceleration, high market concentration, and interest rate sensitivity. IVV offers broad market exposure, yet investors should weigh slowing corporate earnings against historical bullish seasonal trends.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
